Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Trial ID or NCT#

NCT03391778

Status

not recruiting iconNOT RECRUITING

Purpose

This trial will evaluate long term safety of participants who have received GlaxoSmithKline (GSK) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Official Title

Long-Term Follow-Up (LTFU) of Participants Treated With GSK Adoptive Cell Therapies

Eligibility Criteria

Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Participants who have received at least one dose of GSK adoptive cell therapy agent. - Participants who have completed GSK sponsored or supported interventional study or have withdrawn from it. - Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy. - Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. - The investigator is responsible for review of medical history. - Capable of giving signed informed consent.
Exclusion Criteria:
  1. - None
View All Criteria
Show Less

Investigator(s)

Kristen N Ganjoo
Kristen N Ganjoo
Sarcoma specialist, Medical oncologist
Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

Contact

Ileana Aguilar Torres
650-724-1388

View on ClinicalTrials.gov